ProCE Banner Activity

MOUNTAINEER-03 (NCT05253651) is a global, open-label,  randomized, phase 3 study of tucatinib with trastuzumab and  mFOLFOX6 versus standard of care for the first-line treatment of  HER2+ and RAS wild-type mCRC

Slideset

Tanios Bekaii-Saab, MD discusses "MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress." in this virtual poster presentation.

Released: February 01, 2023

Expiration: January 31, 2024